

Supplementary Table S1: Statistical output of comparisons of tumor growth for each treatment group represented in Figure 1

Treatment	PBS	TEM+IRI	IC	TEM+IRI + IC	12 Gy	TEM+IRI + 12 Gy
TEM+IRI	****					
IC	***	ns				
TEM+IRI + IC	****	ns	*			
12 Gy	****	***	****	*		
TEM+IRI + 12 Gy	****	**	****	ns	ns	
TEM+IRI + IC + 12 Gy	****	****	****	**	ns	ns

ns = not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001

Supplementary Table S2: Statistical output of comparisons of tumor growth for each treatment group represented in Figures 2 and 3. p values <0.05 are highlighted.


[illegible]

Supplementary Table S3: Statistical output of comparisons of response rate for each treatment group represented in Figures 2 and 3.

Treatment	CAIR	CAIR minus CpG	CAIR minus α CD40	CAIR minus α CTLA4	CAIR minus RT	CAIR minus IC	CAIR minus CpG/ α CTLA4	CAIR minus α CD40/ α CTLA4	CAIR minus CpG/ α CD40
RT	***	***	***	**	ns	ns	ns	ns	ns
CAIR		ns	ns	ns	*	**	ns	*	ns
CAIR minus CpG			ns	ns	*	**	ns	*	ns
CAIR minus α CD40				ns	*	**	ns	*	ns
CAIR minus α CTLA4					*	**	ns	*	ns
CAIR minus RT						ns	ns	ns	ns
CAIR minus IC							ns	ns	ns
CAIR minus CpG/ α CTLA4								ns	ns
CAIR minus α CD40/ α CTLA4									ns

ns = not significant; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

Weight of mice during treatments with anti-CD40



Supplemental Figure S1: C56BL/6 mice bearing 17 mm³ 9464D-GD2 tumors were not treated, or received anti-CD40 (0.5 mg/mouse intraperitoneally) on days 1 and 8. Mouse weights were obtained every 2–3 days. There were 5 mice per group. Mouse weight dropped ~10% over 4 days following the first dose, with minimal weight loss after the 2nd dose.